ABCL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
10.6M
+162.7%
4.0M
-51.3%
8.3M
-81.5%
44.9M
+400.9%
9.0M
Cost of Revenue
0
0
0
0
0
Gross Profit
10.6M
+162.7%
4.0M
-51.3%
8.3M
-81.5%
44.9M
+400.9%
9.0M
Operating Expenses
64.0M
-4.3%
66.8M
+1.5%
65.8M
-10.4%
73.4M
-13.8%
85.2M
R&D
43.5M
-5.3%
46.0M
-1.4%
46.7M
-6.8%
50.1M
-9.0%
55.0M
SG&A
13.6M
-1.7%
13.8M
+12.3%
12.3M
-28.4%
17.2M
-31.0%
25.0M
Operating Income
-53315000
+15.1%
-62777000
-9.1%
-57519000
-101.2%
-28582000
+62.5%
-76278000
EBITDA
-44659000
+22.5%
-57638000
-13.7%
-50681000
-93.5%
-26191000
+62.1%
-69181000
Net Income
-40758000
+26.5%
-55427000
-28.4%
-43165000
-382.6%
-8945000
+84.3%
-57119000
EPS (Basic)
$-0.13
+27.8%
$-0.18
-28.6%
$-0.14
-366.7%
$-0.03
+84.2%
$-0.19
EPS (Diluted)
$-0.13
+27.8%
$-0.18
-28.6%
$-0.14
-366.7%
$-0.03
+84.2%
$-0.19
Shares (Diluted)
318.1M
+4.1%
305.6M
+0.8%
303.1M
+1.1%
299.8M
+0.3%
298.9M
AbCellera Biologics Inc. Common Shares (ABCL) — Financials